Regulatory

What regulators did, with the date we checked it.

A brick and glass office building on the FDA campus.

FDA Warning Letter Says Empower Pharmacy's Compounded Semaglutide and Tirzepatide Appear to Be Copies

FDA says Empower's compounded semaglutide and tirzepatide with added ingredients appear to be copies of approved drugs. It is FDA's position, not a ruling.

SemaglutideFDA-approvedCompounded versions: not FDA-approved

TirzepatideFDA-approvedCompounded versions: not FDA-approved

October 31, 2026

The concrete facade of the Hubert H. Humphrey Building seen from the street.

Regulatory

HHS Issues Interim Policy on Compounding Six Peptides, Including BPC-157 and TB-500

HHS says it does not intend to act against some 503A compounding of six peptides, under conditions. It is open for comment and is not FDA approval.

BPC-157Compounded versions: not FDA-approved

TB-500Compounded versions: not FDA-approvedAnimal studies only

October 31, 2026

Map of the southeastern United States with Mississippi and Alabama in solid black.

Regulatory

Alabama and Mississippi Boards Warned on Peptides Before HHS's Interim Policy. How They Fit Is Unclear

Alabama and Mississippi boards told licensees not to compound non-FDA-approved or research-grade peptides. Both predate HHS's policy; the fit is unclear.

October 31, 2026